View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

                                                                    Exhibit 99.1

Investor Contacts:
Elizabeth Foster or Claudia Jones of Neurocrine Biosciences
(858) 617-7600
Media Contact: Liz Frank of Cohn & Wolfe
(212) 798-9734

             NEUROCRINE ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION
                              FOR INDIPLON CAPSULES

           PROMISING NEW TREATMENT OPTION SHOWN TO IMPROVE SLEEP ONSET
                              AND SLEEP MAINTENANCE

San Diego, CA, April 14, 2005 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
announced that they have submitted a New Drug Application (NDA) to the U.S. Food
and Drug Administration (FDA) for indiplon capsules for the treatment of
insomnia in both adult and elderly patients. The filing was resubmitted to the
FDA solely to address formatting difficulties with the electronic common
technical document (e-CTDformat), originally submitted in late 2004, and did not
pertain to the content of the filing.

"Insomnia takes a significant toll on the physical well-being, and emotional
health of sufferers. This submission marks a major milestone in our commitment
to provide people with a safe and effective treatment option," said Gary A.
Lyons, President and CEO of Neurocrine Biosciences. "We believe that indiplon is
an important advancement in the treatment of insomnia because it can provide the
flexibility to address the individual sleep needs of people with insomnia for
short or longer-term use."

The NDA for indiplon tablets will also be resubmitted to the FDA in the second
quarter to address similar formatting difficulties encountered with the e-CTD
format originally submitted in late 2004. Data from a recently completed
clinical trial demonstrating the safety and efficacy of indiplon 15 mg tablets
in adult patients will be added to the submission.

The indiplon NDA filings will contain data from 72 clinical trials and include a
comprehensive safety and efficacy evaluation in more than 7,500 subjects.
Clinical trial results have shown that indiplon capsules and tablets help
patients consistently fall asleep faster, increase the amount of time they sleep
during the night, decrease number of nighttime awakenings and improve overall
sleep quality over the course of short or long-term treatment without evidence
of next day effects.

                                     -MORE-

ABOUT INDIPLON

Indiplon is a unique non-benzodiazapine agent that acts on a specific site of
the GABA-A receptor. Indiplon has been shown to bind selectively to the specific
subtype of GABA-A receptors within the brain believed to be responsible for
promoting sleep. Indiplon was developed to address different types of sleep
problems. Indiplon was licensed from DOV Pharmaceutical in 1998. Upon approval,
indiplon will be copromoted in the US with Pfizer.

Insomnia is a prevalent condition in the United States. According to the
National Sleep Foundation's (NSF) Sleep in America Poll 2005 approximately half
of America's adults report that they experienced at least one symptom of
insomnia a few nights a week or more in the past year. Sleep loss has been found
to impair the ability to perform tasks involving memory, learning, and logical
reasoning, yet few people understand the importance of sufficient sleep.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable
bowel syndrome, eating disorders, pain, and autoimmunity. Neurocrine
Biosciences, Inc. news releases are available through the Company's website via
the Internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking
statements that involve a number of risks and uncertainties. Among the factors
that could cause actual results to differ materially from those indicated in the
forward looking statements are risks and uncertainties associated with
Neurocrine's business and finances in general including, but not limited to,
risk and uncertainties associated with the Company's indiplon program and
planned regulatory activities. Specifically, the risks and uncertainties the
Company faces with respect to its indiplon program include, but are not limited
to; risk that the reformatted indiplon capsule NDA will not be acceptable to the
FDA; risk that the Company will not be able to reformat the indiplon tablet NDA
within the Company's projected timelines risk that the Company will be unable to
reformat the indiplon tablet NDA in a manner acceptable to the FDA; the risk
that regulatory authorities may reject our regulatory submissions or find them
incomplete or insufficient; risk that additional clinical studies may be
required to support submissions for regulatory approval; risk that the indiplon
labeling granted by regulatory authorities may limit the commercial success of
indiplon; risk relating to the Company's dependence on contract manufacturers
for clinical drug supply and compliance with regulatory requirements for
marketing approval; risks associated with the Company's dependence on corporate
collaborators for commercial manufacturing and marketing and sales activities;
uncertainties relating to patent protection and intellectual property rights of
third parties; risks and uncertainties relating to competitive products and
technological changes that may limit demand for the Company's products; risk
that the Company will be unable to raise additional funding required to complete
development of all of its product candidates; and the other risks described in
the Company's report on Form 10-K for the year ended December 31, 2004.
Neurocrine undertakes no obligation to update the statements contained in this
press release after the date hereof.


                                      ###